Last reviewed · How we verify
NCT04312295
ACP Simulation-based Communication Training Program for Nurses Discussing ACP With Chronic Kidney Disease Patients
NA trial testing ACP-SCT program in Chronic Kidney Diseases in 96 participants. Completed in 26 March 2020.
26 December 2019
Quick facts
| Lead sponsor | Kaohsiung Medical University Chung-Ho Memorial Hospital |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 96 |
| Start date | 19 September 2019 |
| Primary completion | 26 December 2019 |
| Estimated completion | 26 March 2020 |
| Sites | 1 location across Taiwan |
Drugs / interventions tested
- ACP-SCT program
Conditions studied
- Chronic Kidney Diseases — all drugs for Chronic Kidney Diseases →
Sponsor
Kaohsiung Medical University Chung-Ho Memorial Hospital
Who can join
20 and older, any sex, with Chronic Kidney Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study was to evaluate the effects of ACP simulation-based communication training program (ACP-SCT program) for nurses to discuss ACP with chronic kidney disease patients
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
The development and pilot testing of an ACP simulation-based communication-training program: Feasibility and acceptability.
Chen JO, Chang SC, Lin CC. · · 2021 · cited 5× · PMID 34428209 · DOI 10.1371/journal.pone.0254982
Verify or expand the search:
- PubMed search for NCT04312295
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Chronic Kidney Diseases
Currently open trials in the same condition.
- NCT06593392 — Safety and Tolerability of Difelikefalin in Adolescents on Haemodialysis With Moderate-to-Severe Pruritus · Phase 2 · recruiting
- NCT07358572 — Eye-Brain-Kidney in CKD · recruiting
- NCT06463483 — Automated Insulin Delivery in Adults With Advanced Kidney Disease · NA · recruiting
- NCT06927024 — Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) in Chronic Kidney Disease (CKD) · NA · recruiting
- NCT07115953 — Streamlined Denervation With spYral For an Optimized Treatment (SPYRAL SWYFT) in Subjects With Uncontrolled Hypertension · NA · recruiting
Other Kaohsiung Medical University Chung-Ho Memorial Hospital trials
Trials by the same sponsor.
- NCT07342426 — High and Low Dose High-intensity Laser Therapy Lateral Epicondylitis · Phase 4 · recruiting
- NCT07346469 — Exploring the Effects of Magnesium Ions on Peripheral Neuropathy, Serum Magnesium Ion Concentration,Sleep Quality, and Q · NA · not yet recruiting
- NCT07154407 — AI-assisted Masticatory Muscle Training in Patients With Schizophrenia · NA · not yet recruiting
- NCT07154628 — Effect of Topical Lidocaine Spraying on the Vocal Cords Before Intubation During Robotic Surgery: a Randomized Controlle · Phase 4 · not yet recruiting
- NCT07126444 — Effects of an Exercise Snack Intervention on Employee Health and Work Performance · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04312295 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Kaohsiung Medical University Chung-Ho Memorial Hospital
- Last refreshed: 2 September 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04312295.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing